This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
5 Niche ETFs Sizzling This Summer
by Sweta Killa
Wall Street has been shining bright this summer thanks to upbeat corporate earnings, renewed optimism in a sustained economic recovery, and the Fed's dovish view.
Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults
by Zacks Equity Research
Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.
5 Top-Ranked ETFs That Outperformed in August
by Sweta Jaiswal, FRM
Let's take a look at some top-ranked ETFs that outperformed Wall Street in August.
Merck (MRK) Begins Molnupiravir Study for COVID Prevention
by Zacks Equity Research
Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.
AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq
by Zacks Equity Research
FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.
4 Small-Cap ETFs & Stocks to Explode Higher
by Sweta Killa
With renewed optimism over a sustained economic recovery and robust corporate earnings growth, the small-cap space is set to explode higher.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.
5 Tech Stocks Leading the Latest Nasdaq ETF Rally
by Sweta Killa
Most of the rally was powered by renewed buying in the high-growth tech giants as tapering fears ease as well as optimism over a sustained economic recovery.
FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels
by Kinjel Shah
The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $46.04 in the latest trading session, marking a -0.07% move from the prior day.
5 Sector ETFs That Beat the Market in August
by Sweta Killa
Most of the rally was powered by a huge vaccination drive, upbeat corporate earnings and the Fed's dovish comments that have renewed optimism for sustained global economic recovery.
J&J's (JNJ) HIV Vaccine Study in Young African Women Fails
by Zacks Equity Research
J&J's (JNJ) mid-stage study shows HIV vaccine fails to provide enough protection against HIV in young women in Africa.
5 Stocks That Power S&P 500 ETF in August
by Sweta Killa
The S&P 500 wrapped up its seventh-straight month of gains with the longest winning streak since the 10-month run that ended in December 2017.
Merck's (MRK) Keytruda Gets Full Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gets full approval from the FDA as a first-line treatment for bladder cancer, after having enjoyed accelerated approval for the indication.
5 Top Picks to Boost Portfolio in Historically Weak September
by Nalak Das
We have narrowed down our search to five stocks that have provided more than 20% returns year to date. These are: DKS, KSS, ANF, RCII and HPQ.
Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports
by Zacks Equity Research
Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.
Pfizer's (PFE) Abrocitinib Betters Dupixent in Eczema Study
by Zacks Equity Research
Top-line data from the head-to-head JADE DARE study showed Pfizer's (PFE) abrocitinib to be statistically superior compared to Sanofi (SNY)/Regeneron's (REGN) Dupixent for the primary efficacy endpoints.
Tech Sector Outperforms in August: 5 Best ETFs
by Sweta Killa
With renewed optimism over global economic recovery and robust earnings, the technology sector is back and has been outperforming in August.
5 Most-Loved ETFs of Last Week
by Sweta Killa
ETFs overall gathered about $8.5 billion capital last week (ending Aug 26), bringing inflows of $569.6 billion year to date.
Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal
by Zacks Equity Research
Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five years with moderate-to-severe atopic dermatitis.
Mega-Cap Growth ETF (MGK) Hits New 52-Week High
by Sweta Killa
This mega-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
Best Small/Mid-Cap ETFs of Last Week
by Sanghamitra Saha
The Russell 2000 Index was a winner last week. These ETFs gained immensely last week.
7 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. News of zero new cases in China, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine and no new flare-up in taper talks led to the gains.
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings